In summary, a combination of erlotinib with hypofractionated thoracic RT has the potential to significantly improve local tumor control in patients with non-small-cell lung cancer, based on theoretical considerations of EGFR inhibition, increased tumor cell killing with larger RT fractions and preclinical evidence for synergism between RT and erlotinib.